JPRN-UMIN000003394
Completed
Phase 2
Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer with EGFR Mutation (CJLSG0907) - Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer with EGFR Mutation
Central Japan Lung Study Group0 sites23 target enrollmentMarch 29, 2010
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Central Japan Lung Study Group
- Enrollment
- 23
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Active infection 2\) Fever 3\) Serious disease condition 4\) Active double cancer 5\) Symptomatic brain metastasis 6\) Cavity fluid retention difficult to control 7\) Severe drug allergy 8\) Pregnancy or lactation 9\) EGFR mutation (exon 20\) 10\) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906)JPRN-UMIN000003393Central Japan Lung Study Group53
Completed
Phase 2
Phase II study of Pemetrexed + Carboplatin as first line therapy for nonsquamous non-small cell lung cancer with interstitial pneumoniaJPRN-UMIN000011325Central Japan Lung Study Group (CJLSG)25
Recruiting
Phase 2
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer (EGFR mutation status Negative)JPRN-UMIN000005991Toho University Omori Medical Center35
Completed
Phase 2
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003770Osaka Lung Cancer Study Group40
Completed
Phase 2
A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003755Dept. of Respiratory Medicine, Osaka University Hospital40